Picture [LSA] – The Business Web Portal 650x89px
Document › Details

Lophius Biosciences GmbH. (5/17/10). "Press Release: Closing of a 2nd Financing Round and Appointment of a New CEO. Lophius Closed 2nd Financing Round and Appoints Dr. Michael Lutz as a New CEO".

Region Region Germany
Organisations Organisation Lophius Biosciences GmbH
  Organisation 2 S-Refit AG
  Group Sparkassen-Finanzgruppe (DE) [FICTIVE UNIT, NOT OFFICIAL GROUP!] (Group)
Products Product diagnostic technology
  Product 2 diagnostic test
Index term Index term Lophius–SEVERAL: investment, 201005 2nd financing round €1.6m S-Refit + HTGF + Bayernkapital
Person Person Lutz, Michael (GATC 201004– LifeCodexx AG CEO before Clinical Data/Cogenics before Epidauros before SuNyx)

Lophius Biosciences announced today that the company has successfully closed a 2nd round financing with a value of around 1,6 m EUR. The investment of S-Refit, the new lead investor, is strongly supplemented by follow up investments from existing investors High-Tech Gruenderfonds and Bayernkapital. The financing will be used to boost the development of the company with a strong focus on commercialization of existing diagnostic products and the generation of new tests based on the company´s proprietary technology platforms.

With immediate effect, Dr. Michael Lutz has been appointed as Lophius´ new CEO. In this function, he replaces the existing managing directors PD Dr. Deml and Marc Akteries who will remain within the company in leading positions. Dr. Michael Lutz has significant expertise in building up and managing of innovative biotech companies. He supports Lophius since Sep. 2009 as coach and advisor. Before, Dr. Lutz was Global General Manager of Cogenics and CEO of Epidauros.

Bertram Gilka-Bötzow from S-Refit commented: "We are delighted to jointly support Lophius Biosciences with the existing investors High-Tech Gruenderfonds and Bayernkapital. Lophius is a promising and innovative company further strengthening the local biotech hotspot in Regensburg. With the appointment of Dr. Michael Lutz as experienced CEO of small and medium-sized Biotech companies a major milestone has been achieved to ensure the future growth and development of the company."

"Within a short period we were able to secure S-Refit as new lead investor. S-Refit optimally fits to Lophius´ future development based on its investment strategy and local presence and was highly convinced by the company quality" said Dr. Michael Lutz, Lophius´ new CEO of Lophius. "At this point I would like to take the opportunity to thank the outgoing management, in particular PD Dr. Deml for their hard work in building up the company during the seed investment phase."

Record changed: 2017-04-02


Picture [LSA] – The Business Web Portal 650x89px

More documents for Lophius Biosciences GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [LSA] – The Business Web Portal 650x89px

» top